Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8441614 | European Journal of Cancer | 2016 | 10 Pages |
Abstract
The IGF-1R pathway is an interesting target for ES and should be explored further, as biomarkers to select patients that might benefit from treatment are lacking. PARP inhibitors as single agent have so far failed to show improvement in outcome. Future directions include dual insulin receptor/IGF-1R blockade with linsitinib as well as chemotherapy-PARP combinations. Both therapeutic strategies are currently being explored.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Annemiek M. van Maldegem, Judith V.M.G. Bovée, Elleke F.P. Peterse, Pancras C.W. Hogendoorn, Hans Gelderblom,